We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





DiaSys Showcases Expanding Reagents and Instrumentation Portfolio at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: The respons940 clinical chemistry analyzer was on display at AACC 2022 (Photo courtesy of DiaSys)
Image: The respons940 clinical chemistry analyzer was on display at AACC 2022 (Photo courtesy of DiaSys)

DiaSys Diagnostic Systems (Holzheim, Germany) is showcasing its expanding product portfolio of analyzers and POCT instruments with a special focus on its reagents, at the 73rd AACC Annual Scientific Meeting & Clinical Lab Expo. Vidan Diagnostics (San Antonio, TX, USA), in partnership with Diasys, is also attending the event where it will feature the recently launched next generation Beta-hydroxybutyrate assay used to assist in the determination of diabetic ketoacidosis (DKA).

At the DiaSys AACC 2022 booth, the focus will be on the company’s reagents HDL-c direct FS, LDL-c direct FS, Cystatin C FS, Procalcitonin FS and CRP FS. The company’s innovative new reagents, HDL-c direct FS and LDL-c direct FS, are homogenous assays for direct determination of high-density lipoproteins (HDL) and low-density lipoproteins (LDL). The high quality reagents offer long calibration and onboard stability of up to four months. Combined with wide measuring ranges and good precision at clinical cut-off points, DiaSys assays HDL-c direct FS and LDL-c direct FS are of high value for clinical-chemistry laboratories.

DiaSys Cystatin C FS is an immunturbidemetric assay, which can be applied on a broad range of clinical chemistry analyzers. The assay is characterized by an outstanding analytical sensitivity in addition to superior correlation with nephelometry. It has excellent onboard and calibration stabilities up to 12 weeks and a high prozone security. The standardized test is essential for reliable kidney diagnosis of clinical-chemistry laboratories.

DiaSys Procalcitonin FS is a fluid-stable, particle enhanced immunoturbidimetric assay with outstanding onboard and calibration stability, providing a convenient workflow on clinical chemistry analyzers. Determinations of PCT in serum and plasma within the measuring range from 0.2 ng/mL to 50 ng/mL can be performed with high precision at clinical cut-off levels for sepsis. The performance is complemented by high tolerance to endogenous interferents and various therapeutics used in sepsis management. Procalcitonin FS shows a good correlation to established methods. Results from ring trials and a publication demonstrate the strengths of the assay.

DiaSys CRP FS is a liquid-stable immunoturbidimetric test with dedicated ready-to-use calibrators and controls. The test results are fully quantitative which allows true differentiation of borderline cases. The test is standardized to the international reference material, has a wide measuring range, high prozone security and excellent correlation to competitor tests. The test is easily applicable to clinical chemistry analyzers with a variety of instrument applications available.

Additionally, DiaSys will demonstrate the respons 940 fully automatic random access analyzer (RAM) with a sample throughput of 400 (640 incl. ISE) tests/hour. Due to durable quartz cuvettes, low reaction volume, maintenance free photometer and intuitively operated software, respons 940 offers the economic use and reliability required in small to medium sized labs. In combination with DiaSys' high quality reagents perfectly matching to respons 940 highest results security and therefore, a minimized number of reruns can be assured.

Vidan’s next generation Beta-hydroxybutyrate assay for reliable ketosis management comprises prefilled reagent kits that make it easy to load directly onto Architect and Beckman AU clinical chemistry systems. Its Lipid Clearing System (LCS) overcomes the burden of lipemia by eliminating turbidity in the sample before a measurement is performed. Its superior stability reduces the frequency of calibration and allows the reagent to stay onboard longer.
 

Related Links:
DiaSys Diagnostic Systems 
Vidan Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.